BRISBANE, Calif., May 9 /PRNewswire-FirstCall/ -- WHAT: VaxGen, Inc. will hold a conference call to discuss modifications to its contract with the U.S. Department of Health and Human Services to provide 75 million doses of VaxGen's anthrax vaccine. This conference call will be preceded by a news release at 1 p.m. PT/4 p.m. ET on Wednesday, May 10. The company will make no statements prior to the conference call. WHEN: 1:30 p.m. PT/4:30 p.m. ET, Wednesday, May 10, 2006 To listen to a live webcast of the presentation, go to Webcasts in the Investor Relations section of VaxGen's web site at www.vaxgen.com and click on "Anthrax Contract Modification." HOW: Live Call: Domestic: 800-374-0113 International: 706-758-9607 No passcode required. Replay: Domestic: 800-642-1687 International: 706-645-9291 Passcode: 9189416 About VaxGen
VaxGen, Inc. is a biopharmaceutical company engaged in the development, manufacture and commercialization of biologic products for the prevention and treatment of human infectious diseases, including anthrax and smallpox. VaxGen has been awarded an $877.5 million contract by the U.S. Department of Health and Human Services to provide 75 million doses of a recombinant anthrax vaccine for civilian biodefense. Based in Brisbane, Calif., VaxGen operates a wholly owned manufacturing facility in California and owns 21% of Celltrion, Inc., a company in the Republic of Korea established to provide contract manufacturing to the global pharmaceutical industry. For more information, please visit the company's web site at www.vaxgen.com.
(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO )
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk photodesk@prnewswire.comVaxGen, Inc.CONTACT: Kesinee Yip, +1-650-624-2304, for VaxGen, Inc.
Web site: http://www.vaxgen.com//
